Expertise in
5
conditions

Dr. Barry S. Horowitz

Endocrinology
Guidewell Sanitas I LLC
1515 N Flagler Dr, 
West Palm Beach, FL 
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
5
conditions
Guidewell Sanitas I LLC
1515 N Flagler Dr, 
West Palm Beach, FL 

Overview

Barry Horowitz is an Endocrinologist practicing medicine in West Palm Beach, Florida.

Dr. Horowitz is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Type 1 Diabetes (T1D), Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Obesity in Children.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 11 clinical trials. Dr. Horowitz is currently accepting new patients.

Specialties

Endocrinology

Licenses

Internal Medicine in FL

Hospital Affiliations

Boca Raton Regional Hospital
Jupiter Medical Center
Good Samaritan Medical Center
Hca Florida Jfk Hospital

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

Guidewell Sanitas I LLC
1515 N Flagler Dr, West Palm Beach, FL 33401

Additional Areas of Focus

Dr. Horowitz has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Suspended
Publish Date: March 14, 2023
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 01, 2021
Intervention Type: Device
Study Phase: Not Applicable
An Assessment of the Impact of an App Based Diabetes Training Program in Conjunction With the Use of BD Nano 2nd Gen 4mm Pen Needle on Diabetes Self-efficacy in People With Type 2 Diabetes
An Assessment of the Impact of an App Based Diabetes Training Program in Conjunction With the Use of BD Nano 2nd Gen 4mm Pen Needle on Diabetes Self-efficacy in People With Type 2 Diabetes
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

7 Total Publications

Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial.
Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial.
Journal: JAMA network open
Published: February 14, 2025
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral required
Before you request

Office

10150 Hagen Ranch Rd Ste 201, 
Boynton Beach, FL 
 (16.0 miles away)
561-374-8969
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Mellman is an Endocrinologist practicing medicine in Boynton Beach, Florida. Dr. Mellman is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Type 1 Diabetes (T1D), Obesity in Children, Hypothyroidism, and Type 2 Diabetes (T2D). Dr. Mellman is currently accepting new patients.

Expertise in
44
conditions
Dr. Alan Feldman
Endocrinology
Expertise in
44
conditions
Dr. Alan Feldman
Endocrinology
Referral required
Before you request

Office

4600 Military Trl Ste 203, 
Jupiter, FL 
 (15.4 miles away)
561-626-9041
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alan Feldman is an Endocrinologist practicing medicine in Jupiter, Florida. Dr. Feldman is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Hyperparathyroidism, Type 2 Diabetes (T2D), Familial Isolated Hyperparathyroidism, and Osteitis Fibrosa. Dr. Feldman is currently accepting new patients.

Expertise in
50
conditions
Expertise in
50
conditions
Referral required
Before you request

Aleksandra Kraeher MD PA

4600 Military Trl Ste 218, 
Jupiter, FL 
 (15.4 miles away)
561-626-9041
Languages Spoken:
English, Polish
See accepted insurances
Accepting New Patients
Offers Telehealth

Aleksandra Kraeher is an Endocrinologist practicing medicine in Jupiter, Florida. Dr. Kraeher is highly rated in 50 conditions, according to our data. Her clinical expertise encompasses Hypothyroidism, Obesity in Children, Diabetic Nephropathy, and Type 2 Diabetes (T2D). Dr. Kraeher is currently accepting new patients.

Frequently Asked Questions about Dr. Barry S. Horowitz

How do I make an appointment with Dr. Barry S. Horowitz?

You can book an appointment with Dr. Barry S. Horowitz by calling their office at 561-659-6336. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Barry S. Horowitz a top-rated expert for Type 1 Diabetes (T1D)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Barry S. Horowitz is classified as an Distinguished expert for Type 1 Diabetes (T1D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Barry S. Horowitz specialize in?

While Dr. Barry S. Horowitz is a Endocrinology, they have specific expertise in Type 1 Diabetes (T1D), Maturity Onset Diabetes of the Young, and Type 2 Diabetes (T2D). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Barry S. Horowitz participate in research or clinical trials?

Yes. Dr. Barry S. Horowitz has published 7 articles and abstracts on conditions like Type 1 Diabetes (T1D). You can view a list of Dr. Barry S. Horowitz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Barry S. Horowitz accept my insurance?

Dr. Barry S. Horowitz accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 561-659-6336 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Horowitz's expertise for a condition
ConditionClose
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile